BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Díaz-Jiménez D, Núñez LE, Beltrán CJ, Candia E, Suazo C, Álvarez-Lobos M, González MJ, Hermoso MA, Quera R. Soluble ST2: A new and promising activity marker in ulcerative colitis. World J Gastroenterol 2011; 17(17): 2181-2190 [PMID: 21633527 DOI: 10.3748/wjg.v17.i17.2181] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Jiang W, Li X. Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Mol Diagn Ther 2015;19:141-58. [DOI: 10.1007/s40291-015-0142-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
2 Ge C, Lu Y, Shen H, Zhu L. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. Scand J Gastroenterol 2022;:1-12. [PMID: 34994661 DOI: 10.1080/00365521.2021.2022193] [Reference Citation Analysis]
3 Pei C, Barbour M, Fairlie-Clarke KJ, Allan D, Mu R, Jiang HR. Emerging role of interleukin-33 in autoimmune diseases. Immunology. 2014;141:9-17. [PMID: 24116703 DOI: 10.1111/imm.12174] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 6.9] [Reference Citation Analysis]
4 Sands BE. Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology. 2015;149:1275-1285.e2. [PMID: 26166315 DOI: 10.1053/j.gastro.2015.07.003] [Cited by in Crossref: 150] [Cited by in F6Publishing: 135] [Article Influence: 21.4] [Reference Citation Analysis]
5 Boga S, Alkim H, Koksal AR, Ozagari AA, Bayram M, Tekin Neijmann S, Sen I, Alkim C. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity. J Investig Med 2016;64:1016-24. [PMID: 27001944 DOI: 10.1136/jim-2016-000062] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
6 Jung SM, Lee J, Baek SY, Lee JH, Lee J, Park K, Park S, Kim H, Kwok S. The Interleukin 33/ST2 Axis in Patients with Primary Sjögren Syndrome: Expression in Serum and Salivary Glands, and the Clinical Association. J Rheumatol 2015;42:264-71. [DOI: 10.3899/jrheum.140234] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
7 Jenabian MA, El-Far M, Vyboh K, Kema I, Costiniuk CT, Thomas R, Baril JG, LeBlanc R, Kanagaratham C, Radzioch D, Allam O, Ahmad A, Lebouché B, Tremblay C, Ancuta P, Routy JP; Montreal Primary infection and Slow Progressor Study Groups. Immunosuppressive Tryptophan Catabolism and Gut Mucosal Dysfunction Following Early HIV Infection. J Infect Dis 2015;212:355-66. [PMID: 25616404 DOI: 10.1093/infdis/jiv037] [Cited by in Crossref: 73] [Cited by in F6Publishing: 79] [Article Influence: 10.4] [Reference Citation Analysis]
8 Homsak E, Gruson D. Soluble ST2: A complex and diverse role in several diseases. Clin Chim Acta 2020;507:75-87. [PMID: 32305537 DOI: 10.1016/j.cca.2020.04.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
9 Yuan X, Chinnaswamy K, Stuckey JA, Yang CY. Computational Cosolvent Mapping Analysis Leads to Identify Salicylic Acid Analogs as Weak Inhibitors of ST2 and IL33 Binding. J Phys Chem B 2022. [PMID: 35294837 DOI: 10.1021/acs.jpcb.2c00341] [Reference Citation Analysis]
10 Fengming Y, Jianbing W. Biomarkers of inflammatory bowel disease. Dis Markers. 2014;2014:710915. [PMID: 24963213 DOI: 10.1155/2014/710915] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
11 Krzystek-Korpacka M, Kempiński R, Bromke M, Neubauer K. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics (Basel) 2020;10:E367. [PMID: 32498475 DOI: 10.3390/diagnostics10060367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
12 Shen J, Shang Q, Wong CK, Li EK, Wang S, Li RJ, Lee KL, Leung YY, Ying KY, Yim CW, Kun EW, Leung MH, Li M, Li TK, Zhu TY, Yu SL, Kuan WP, Yu CM, Tam LS. IL-33 and soluble ST2 levels as novel predictors for remission and progression of carotid plaque in early rheumatoid arthritis: A prospective study. Semin Arthritis Rheum 2015;45:18-27. [PMID: 25798875 DOI: 10.1016/j.semarthrit.2015.02.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
13 Peters CP, Mjösberg JM, Bernink JH, Spits H. Innate lymphoid cells in inflammatory bowel diseases. Immunol Lett 2016;172:124-31. [PMID: 26470815 DOI: 10.1016/j.imlet.2015.10.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
14 Sastre C, Bevers MB, Kimberly WT. Role of Interleukin-1 Receptor-Like 1 (ST2) in Cerebrovascular Disease. Neurocrit Care 2021. [PMID: 34231185 DOI: 10.1007/s12028-021-01284-3] [Reference Citation Analysis]
15 Díaz-Jiménez D, De la Fuente M, Dubois-Camacho K, Landskron G, Fuentes J, Pérez T, González MJ, Simian D, Hermoso MA, Quera R. Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution. BMC Gastroenterol 2016;16:103. [PMID: 27565556 DOI: 10.1186/s12876-016-0520-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
16 Schiering C, Krausgruber T, Chomka A, Fröhlich A, Adelmann K, Wohlfert EA, Pott J, Griseri T, Bollrath J, Hegazy AN. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513:564-568. [PMID: 25043027 DOI: 10.1038/nature13577] [Cited by in Crossref: 560] [Cited by in F6Publishing: 546] [Article Influence: 70.0] [Reference Citation Analysis]
17 Moeinafshar A, Yazdanpanah N, Rezaei N. Diagnostic biomarkers of dilated cardiomyopathy. Immunobiology 2021;226:152153. [PMID: 34784575 DOI: 10.1016/j.imbio.2021.152153] [Reference Citation Analysis]
18 Candia E, Díaz-Jiménez D, Langjahr P, Núñez LE, de la Fuente M, Farfán N, López-Kostner F, Abedrapo M, Alvarez-Lobos M, Pinedo G, Beltrán CJ, González C, González MJ, Quera R, Hermoso MA. Increased production of soluble TLR2 by lamina propria mononuclear cells from ulcerative colitis patients. Immunobiology 2012;217:634-42. [PMID: 22101184 DOI: 10.1016/j.imbio.2011.10.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
19 Xie L, Liao G, Chen H, Xia M, Huang X, Fan R, Peng J, Zhang X, Liu H. Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B. BMC Infect Dis 2019;19:640. [PMID: 31324231 DOI: 10.1186/s12879-019-4261-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Owens BM. Inflammation, Innate Immunity, and the Intestinal Stromal Cell Niche: Opportunities and Challenges. Front Immunol 2015;6:319. [PMID: 26150817 DOI: 10.3389/fimmu.2015.00319] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
21 Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta 2015;443:57-70. [PMID: 25269091 DOI: 10.1016/j.cca.2014.09.021] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 9.5] [Reference Citation Analysis]
22 Artru F, Bou Saleh M, Maggiotto F, Lassailly G, Ningarhari M, Demaret J, Ntandja-wandji L, Pais de Barros J, Labreuche J, Drumez E, Helou DG, Dharancy S, Gantier E, Périanin A, Chollet-martin S, Bataller R, Mathurin P, Dubuquoy L, Louvet A. IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis. Journal of Hepatology 2020;72:1052-61. [DOI: 10.1016/j.jhep.2019.12.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
23 Zhao Q, Chen G. Role of IL-33 and its receptor in T cell-mediated autoimmune diseases. Biomed Res Int 2014;2014:587376. [PMID: 25032216 DOI: 10.1155/2014/587376] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
24 Mueller T, Jaffe AS. Soluble ST2—Analytical Considerations. The American Journal of Cardiology 2015;115:8B-21B. [DOI: 10.1016/j.amjcard.2015.01.035] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
25 Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares de Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Philip G, Lopes J, Carneiro F. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. Therap Adv Gastroenterol 2019;12:1756284819869141. [PMID: 31516554 DOI: 10.1177/1756284819869141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Feigenbaum LZ, Lee D, Ho J. Routine testing of folate levels in geriatric assessment for dementia. J Am Geriatr Soc. 1988;36:755. [PMID: 3136199 DOI: 10.1016/j.cca.2019.07.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
27 Ji GX, Cheng Y, Gao FL, Xie CS, Yang M. Immune modulation by the IL-33/ST2 system in ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2014; 22(12): 1663-1668 [DOI: 10.11569/wcjd.v22.i12.1663] [Reference Citation Analysis]
28 Díaz-Jiménez D, Núñez L, De la Fuente M, Dubois-Camacho K, Sepúlveda H, Montecino M, Torres-Riquelme A, García-González P, Chnaiderman J, Vossenkamper A, MacDonald TT, Simian D, González MJ, Cidlowski JA, Quera R, Hermoso MA. A functional IL1RL1 variant regulates corticosteroid-induced sST2 expression in ulcerative colitis. Sci Rep 2017;7:10180. [PMID: 28860510 DOI: 10.1038/s41598-017-10465-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kourkoulis P, Kapizioni C, Michalopoulos G, Andreou N, Papaconstantinou I, Karamanolis G, Gazouli M. Novel potential biomarkers for the diagnosis and monitoring of patients with ulcerative colitis. European Journal of Gastroenterology & Hepatology 2019;31:1173-83. [DOI: 10.1097/meg.0000000000001490] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 García-Miguel M, González MJ, Quera R, Hermoso MA. Innate immunity modulation by the IL-33/ST2 system in intestinal mucosa. Biomed Res Int. 2013;2013:142492. [PMID: 23484079 DOI: 10.1155/2013/142492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
31 Zhang J, Ramadan AM, Griesenauer B, Li W, Turner MJ, Liu C, Kapur R, Hanenberg H, Blazar BR, Tawara I, Paczesny S. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med 2015;7:308ra160-308ra160. [DOI: 10.1126/scitranslmed.aab0166] [Cited by in Crossref: 93] [Cited by in F6Publishing: 92] [Article Influence: 15.5] [Reference Citation Analysis]
32 Mueller T, Dieplinger B. The Presage(®) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn 2013;13:13-30. [PMID: 23256700 DOI: 10.1586/erm.12.128] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
33 Griesenauer B, Paczesny S. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol 2017;8:475. [PMID: 28484466 DOI: 10.3389/fimmu.2017.00475] [Cited by in Crossref: 190] [Cited by in F6Publishing: 191] [Article Influence: 38.0] [Reference Citation Analysis]
34 Bandara G, Beaven MA, Olivera A, Gilfillan AM, Metcalfe DD. Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33. Eur J Immunol 2015;45:3034-44. [PMID: 26256265 DOI: 10.1002/eji.201545501] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 7.0] [Reference Citation Analysis]
35 Pastorelli L, De Salvo C, Vecchi M, Pizarro TT. The role of IL-33 in gut mucosal inflammation. Mediators Inflamm 2013;2013:608187. [PMID: 23766561 DOI: 10.1155/2013/608187] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
36 Idzik M, Poloczek J, Skrzep-poloczek B, Chełmecka E, Jochem J, Stygar D, Czuczejko J. General Rehabilitation Program after Knee or Hip Replacement Significantly Influences Erythrocytes Oxidative Stress Markers and Serum ST2 Levels. Oxidative Medicine and Cellular Longevity 2022;2022:1-11. [DOI: 10.1155/2022/1358858] [Reference Citation Analysis]
37 Ramadan AM, Daguindau E, Rech JC, Chinnaswamy K, Zhang J, Hura GL, Griesenauer B, Bolten Z, Robida A, Larsen M, Stuckey JA, Yang CY, Paczesny S. From proteomics to discovery of first-in-class ST2 inhibitors active in vivo. JCI Insight 2018;3:99208. [PMID: 30046004 DOI: 10.1172/jci.insight.99208] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
38 Takeyama H, Mizushima T, Iijima H, Shinichiro S, Uemura M, Nishimura J, Hata T, Takemasa I, Yamamoto H, Doki Y, Mori M. Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein. Dig Dis Sci. 2015;60:3418-3423. [PMID: 26077975 DOI: 10.1007/s10620-015-3745-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
39 Holgado A, Braun H, Van Nuffel E, Detry S, Schuijs MJ, Deswarte K, Vergote K, Haegman M, Baudelet G, Haustraete J, Hammad H, Lambrecht BN, Savvides SN, Afonina IS, Beyaert R. IL-33trap is a novel IL-33-neutralizing biologic that inhibits allergic airway inflammation. J Allergy Clin Immunol 2019;144:204-15. [PMID: 30876911 DOI: 10.1016/j.jaci.2019.02.028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
40 Wang M, Shen G, Xu L, Liu X, Brown JM, Feng D, Ross RA, Gao B, Liangpunsakul S, Ju C. IL-1 receptor like 1 protects against alcoholic liver injury by limiting NF-κB activation in hepatic macrophages. Journal of Hepatology 2018;68:109-17. [DOI: 10.1016/j.jhep.2017.08.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]